NCT03020134

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

Phase I Study of Pharmacokinetics and Safety of Ravidasvir in Combination With Ritonavir-boosted Danoprevir in Single and Multiple Doses in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Ascletis Pharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the Pharmacokinetics and safety of Ravidasvir in Combination with Ritonavir-boosted Danoprevir in Single and Multiple doses in Healthy Participants

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Ravidasvir	Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
DRUG	Danoprevir	Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
DRUG	Ritonavir	Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
DRUG	Placebo	Placebo

Timeline

• Start date: 2016-07-15
• Primary completion: 2016-08-22
• Completion: 2016-08-22
• First posted: 2017-01-13
• Last updated: 2018-06-29